Kurzius Lawrence Erik purchased $936K of ELAN

Elanco Animal Health (ELAN) shares fell 5% in pre-market trading after Jefferies downgraded the stock to Hold and cut its price target to $24 from $31, citing risks to pricing power in the animal health industry. The analyst expects reduced pricing support and lower growth for Elanco, with concerns echoed by a simultaneous downgrade of Zoetis (ZTS). An Elanco executive's share sale added to the negative sentiment.

Jefferies downgraded Elanco Animal Health (ELAN) to Hold, cutting its price target to $24 from $31. The stock trades at $23.49, with InvestingPro suggesting overvaluation. Analysts cite growth driven by volume, not pricing, and note risks from Zoetis' concessions. Elanco reported Q2 2026 earnings of $0.34 per share on $1.37B revenue, beating estimates. Fitch upgraded Elanco's rating to 'BB+' from 'BB', while Stifel maintained a Buy rating with a $33 target.

Jefferies downgraded Zoetis (ZTS) to Hold from Buy, lowering its price target to $83 from $103. The firm cited concerns about pricing headwinds and lower volume growth, projecting a 2% decline in 2027 EPS. Jefferies also downgraded Elanco to Hold, citing pricing risks, while Fitch upgraded Elanco's ratings and Stifel reiterated a Buy rating.

Elanco Animal Health completed a $120 million expansion of its biologics plant in Kansas, increasing capacity fourfold. The company plans to invest an additional $30 million by 2028, aiming for unconstrained supply of its dermatology product Befrena by early 2027, as demand is twice expectations.

Elanco Animal Health completed a $120M expansion of its Kansas biologics plant, increasing production capacity 4x. The site now serves as the company's center for monoclonal antibody (mAb) manufacturing, with plans for an additional $30M investment by 2028. Elanco acquired the site in 2021 and has since grown its workforce from 30 to over 200 employees. The expansion supports products like Trutect and Befrena, with demand for the latter exceeding expectations.

The FDA approved Capstar (Elanco) and nitenpyram (Felix) for preventing and treating New World screwworm in pets. The drugs are for dogs, cats, and kittens over 4 weeks old. 48 cases confirmed in the U.S. according to the USDA. Elanco and Felix are the manufacturers.